211At-MABG for advanced neuroendocrine cancers such as pheochromocytoma and paraganglioma
Tests different doses of 211At-MABG in adults with advanced neuroendocrine cancers.
Plain-language title generated from the registry record
Registry title: 211At-MABG in Adults With Advanced Neuroendocrine Cancers
Key facts
- Where
- Philadelphia, United StatesSee the site
- Phase
- Phase 1
Where in United States
- University of Pennsylvania/Abramson Cancer CenterPhiladelphia, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pennsylvania
- Trial code
- NCT07661420
- Record updated
- 7 October 2026
- Original description
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).Read full original descriptionShow less
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).
Inclusion: Adult patients, at least 18 years of age; Advanced neuroendocrine cancers requiring systemic therapy and refractory to, ineligible for, declining, or lacking standard treatments; I MIBG imaging indicating MIBG-avid disease (radiotracer uptake above background in at least one tumor site) per Investigator/Sub-Investigator assessment; Participants must provide written informed consent prior to study-specific procedures; ECOG performance status ≤ 2; Adequate organ function including:; Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1,500/mm³; Platelet count ≥ 75,000/mm³; Measured or estimated GFR ≥ 60 mL/min; Serum bilirubin ≤ 1.5x upper limit of normal; ALT/AST each ≤ 2.5x upper limit of normal; Life expectancy at least 3 months as judged by treating physician.
Exclusion: Uncontrolled brain metastasis (Participant must be at least 4 weeks since CNS-directed therapy and no longer requiring corticosteroid therapy); Anticancer therapy, except hormonal therapy or bone supportive therapies, within 14 days of cycle 1 day 1; Serious or unstable medical, psychological, or social conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study; Has a known additional malignancy (other than the disease under study) that has required active systemic treatment within the past 2 years AND for which the natural history or recent/ongoing treatment could likely interfere with study endpoints or safety of the study treatment per Investigator and Medical Director assessment; Women who are pregnant or breast-feeding will not be eligible for this study; Inability to tolerate study procedures in the opinion of the investigator or treating physician.